Begoña Pérez Valderrama

Begoña Pérez Valderrama

Auto-generated profile, based on publicly available information

Begoña Pérez Valderrama

Medical Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2012 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
MMMaría José Méndez-Vidal
María José Méndez-Vidal
EOEsther Martínez Ortega
Esther Martínez Ortega
ÁPÁlvaro Montesa Pino
Álvaro Montesa Pino
BVBegoña Pérez Valderrama
Begoña Pérez Valderrama
RVRuth Viciana
Ruth Viciana

3 July 2024 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
JAJosé Angel Arranz Arija
José Angel Arranz Arija
XMXavier Garcia Del Muro
Xavier Garcia Del Muro
RCRaquel Luque Caro
Raquel Luque Caro
MMMaría José Méndez-Vidal
María José Méndez-Vidal
BPBegoña Pérez-Valderrama
Begoña Pérez-Valderrama
EGEnrique Gonzalez-Billalabeitia
Enrique Gonzalez-Billalabeitia
Testicular germ cell tumors are the most common tumors in adolescent and young men. They are curable malignancies that should be treated with curative intent, minimizing acute and long-term side effects. Inguinal orchiectomy is the main diagnostic procedure, and is also curative for most localized tumors, while patients with unfavorable risk factors for recurrence, or those who are unable or unwilling to undergo close follow-up, may require adjuvant treatment. Patients with persistent markers after orchiectomy or advanced disease at diagnosis should be staged and classified according to the IGCCCG prognostic classification. BEP is the most recommended chemotherapy, but other schedules such as EP or VIP may be used to avoid bleomycin in some patients. Efforts should be made to avoid unnecessary delays and dose reductions wherever possible. Insufficient marker decline after each cycle is associated with poor prognosis. Management of residual masses after chemotherapy differs between patients with seminoma and non-seminoma tumors. Patients at high risk of relapse, those with refractory tumors, or those who relapse after chemotherapy should be managed by multidisciplinary teams in experienced centers. Salvage treatment for these patients includes conventional-dose chemotherapy (TIP) and/or high-dose chemotherapy, although the best regimen and strategy for each subgroup of patients is not yet well established. In late recurrences, early complete surgical resection should be performed when feasible. Given the high cure rate of TGCT, oncologists should work with patients to prevent and identify potential long-term side effects of the treatment. The above recommendations also apply to extragonadal retroperitoneal and mediastinal tumors.

17 February 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
XMXavier Garcia Del Muro
Xavier Garcia Del Muro
BVBegoña P. Valderrama
Begoña P. Valderrama
ACAna Medina Colmenero
Ana Medina Colmenero
OUOLATZ ETXANIZ ULAZIA
OLATZ ETXANIZ ULAZIA
RSRegina Gironés Sarrió
Regina Gironés Sarrió
RARamon Alemany
Ramon Alemany
Purpose: The combination of radiation and immunotherapy potentiated antitumor activity in preclinical models. The purpose of this study is to explore the feasibility, safety, and efficacy of a bladder-preserving approach, including dual immune checkpoint blockade and radiotherapy, in patients with muscle-invasive bladder cancer (MIBC). Patients and Methods: Patients with localized MIBC underwent transurethral resection, followed by durvalumab (1,500 mg) plus tremelimumab (75 mg) every 4 weeks for three doses and concurrent radiotherapy (64–66 Gy to bladder). Patients with residual or relapsed MIBC underwent salvage cystectomy. The primary endpoint was complete response, defined as the absence of MIBC at posttreatment biopsy. Secondary endpoints were bladder-intact disease-free survival, distant metastasis–free survival, and overall survival. Results: Thirty-two patients were enrolled at six centers. Complete response was documented in 26 (81%) patients. Two patients had residual MIBC, and four patients were not evaluated. After a median follow-up of 27 months, 2 patients underwent salvage cystectomy. The 2-year rates for bladder-intact disease-free survival, distant metastasis–free survival, and overall survival were 65%, 83%, and 84%, respectively. The 2-year estimates of non–muscle-invasive bladder relapse, MIBC, and distant metastasis were 3%, 19%, and 16%, respectively. Grade 3 to 4 toxicities were reported in 31% of patients, with diarrhea (6%) and acute kidney failure (6%) being the most frequent. Conclusions: This multimodal approach including durvalumab plus tremelimumab with concurrent radiotherapy is feasible and safe, showing high efficacy in terms of response and eliciting bladder preservation in a large number of patients. Further research on this approach as an alternative to cystectomy is warranted.

26 March 2022 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
BVBegoña P. Valderrama
Begoña P. Valderrama
AGAranzazu González-del-Alba
Aranzazu González-del-Alba
RMRafael Morales-Barrera
Rafael Morales-Barrera
IFIgnacio Peláez Fernández
Ignacio Peláez Fernández
SVSergio Vázquez
Sergio Vázquez
JAJosé Ángel Arranz Arija
José Ángel Arranz Arija
Most muscle-invasive bladder cancer (BC) are urothelial carcinomas (UC) of transitional origin, although histological variants of UC have been recognized. Smoking is the most important risk factor in developed countries, and the basis for prevention. UC harbors high number of genomic aberrations that make possible targeted therapies. Based on molecular features, a consensus classification identified six different MIBC subtypes. Hematuria and irritative bladder symptoms, CT scan, cystoscopy and transurethral resection are the basis for diagnosis. Radical cystectomy with pelvic lymphadenectomy is the standard approach for muscle-invasive BC, although bladder preservation is an option for selected patients who wish to avoid or cannot tolerate surgery. Perioperative cisplatin-based neoadjuvant chemotherapy is recommended for cT2-4aN0M0 tumors, or as adjuvant in patients with pT3/4 and or pN + after radical cystectomy. Follow-up is particularly important after the availability of new salvage therapies. It should be individualized and adapted to the risk of recurrence. Cisplatin–gemcitabine is considered the standard first line for metastatic tumors. Carboplatin should replace cisplatin in cisplatin-ineligible patients. According to the EMA label, pembrolizumab or atezolizumab could be an option in cisplatin-ineligible patients with high PD-L1 expression. For patients whose disease respond or did not progress after first-line platinum chemotherapy, maintenance with avelumab prolongs survival with respect to the best supportive care. Pembrolizumab also increases survival versus vinflunine or taxanes in patients with progression after chemotherapy who have not received avelumab, as well as enfortumab vedotin in those progressing to first-line chemotherapy followed by an antiPDL1/PD1. Erdafitinib may be considered in this setting in patients with FGFR alterations. An early onset of supportive and palliative care is always strongly recommended.

9 August 2023 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
MMMaría José Méndez-Vidal
María José Méndez-Vidal
MQMartin Lázaro Quintela
Martin Lázaro Quintela
NLNuria Lainez-Milagro
Nuria Lainez-Milagro
BPBegoña Perez-Valderrama
Begoña Perez-Valderrama
CRCristina Suárez Rodriguez
Cristina Suárez Rodriguez
AGAranzazu González-del-Alba
Aranzazu González-del-Alba
Renal cancer is the seventh most common cancer in men and the tenth in women. The aim of this article is to review the diagnosis, treatment, and follow-up of renal carcinoma accompanied by recommendations with new evidence and treatment algorithms. A new pathologic classification of RCC by the World Health Organization (WHO) was published in 2022 and this classification would be considered a “bridge” to a future molecular classification. For patients with localized disease, surgery is the treatment of choice with nephron-sparing surgery recommended when feasible. Adjuvant treatment with pembrolizumab is an option for intermediate-or high-risk cases, as well as patients after complete resection of metastatic disease. More data are needed in the future, including positive overall survival data. Clinical prognostic classification, preferably IMDC, should be used for treatment decision making in mRCC. Cytoreductive nephrectomy should not be deemed mandatory in individuals with intermediate-poor IMDC/MSKCC risk who require systemic therapy. Metastasectomy can be contemplated in selected subjects with a limited number of metastases or long metachronous disease-free interval. For the population of patients with metastatic ccRCC as a whole, the combination of pembrolizumab–axitinib, nivolumab–cabozantinib, or pembrolizumab–lenvatinib can be considered as the first option based on the benefit obtained in OS versus sunitinib. In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib. As for individuals with advanced RCC previously treated with one or two antiangiogenic tyrosine-kinase inhibitors, nivolumab and cabozantinib are the options of choice. When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.

17 September 2025 in Clinical and Translational Oncology
Verified
Journal Article
Open access
PDF file
JPJavier Puente
Javier Puente
ARAlejo Rodríguez-Vida
Alejo Rodríguez-Vida
ESElena Sevillano
Elena Sevillano
SESergio Vázquez Estévez
Sergio Vázquez Estévez
Carlos Alvarez-FernandezCarlos Alvarez-Fernandez
Carlos Alvarez-Fernandez
BVBegoña P. Valderrama
Begoña P. Valderrama
This clinical guideline provides evidence-based recommendations for the diagnosis, staging, and management of bladder cancer across all disease stages. In these guidelines (updated in 2025), we summarize current evidence and available therapies for the medical management of urothelial cancer.